DNX-2401 adenovirus

From Glioblastoma Treatments
Jump to navigationJump to search


Property Information
Drug Name DNX-2401 adenovirus
FDA Approval Not specified
Used for Not specified
Clinical Trial Phase Not specified
Clinical Trial Explanation Not specified
Common Side Effects Not specified
OS without Not specified
OS with Not specified
PFS without Not specified
PFS with Not specified
Usefulness Rating Not rated
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified



From Ben Williams Book: Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse events attributable to the virus being reported. 3 of 25 patients responded to the treatment with complete, durable responses of 42, 32, and 29 months so far. These three complete responders had vigorous immune responses, with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance for type-1 anti-tumor immune responses.Property "Has original text" (as page type) with input value "Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO</br>trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor.</br>Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented</br>at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma</br>patients had been treated, with no adverse events attributable to the virus being reported.</br>3 of 25 patients responded to the treatment with complete, durable responses of 42, 32,</br>and 29 months so far. These three complete responders had vigorous immune responses,</br>with 10-1000 fold increased levels of interleukin-12p70, a cytokine with great importance</br>for type-1 anti-tumor immune responses." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.

Loading comments...